Glenmark receives USFDA final approval for Voriconazole Tablets

04 Sep 2015 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Voriconazole Tablets, 50 mg and 200 mg, the therapeutic equivalent of Vfend Tablets, 50 mg and 200 mg of PF Prism C.V. (Prism).

The Vfend market achieved annual sales of approximately $91.4 million, according to IMS Health sales data for the 12 month period ending July 2015.

Glenmark’s current portfolio consists of 102 products authorized for distribution in the US marketplace and 63 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1035.00 6.95 (0.68%)
24-May-2024 15:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1486.55
Dr. Reddys Lab 5860.25
Cipla 1482.55
Zydus Lifesciences 1072.35
Lupin 1613.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.